Medical Xpress

MAY 16, 2023

That was the case when Thilini Gamage was to carry out one of the studies in her doctoral work with Professor Eirik Frengen at the Institute of Clinical Medicine, University of Oslo. They study gene variation and mutations that cause rare genetic diseases. A mutation is a permanent change in the genetic material.

In-Vitro 92

In-Vitro In-Vivo Genetic Disease Genetics 92

pharmaphorum

OCTOBER 6, 2022

Disease modelling Gulf War Illness. In the mid-to-late 1990s, an unexplained illness began to emerge in army bases across the US. Symptoms and their severity ranged across individuals, and included fatigue, musculoskeletal pain, skin rashes, headaches, and gastrointestinal issues. Tinker, tailor, soldier, therapy.

In-Vivo 98

In-Vivo Research Genetics Drugs 98

pharmaphorum

NOVEMBER 4, 2022

She has also held senior positions at Roche, Novo Nordisk, and Lundbeck, and trained as a medical doctor in Denmark before completing an MBA in Switzerland. “It’s so exciting to be part of this company as we share our passion to deliver innovative medicines to patients faster,” she said in a LinkedIn post.

In-Vivo 59

In-Vivo Gene Therapy Doctors Doctor 59

pharmaphorum

JANUARY 25, 2023

Digital therapeutics company Woebot Health has announced enrolment of the first patient in a pivotal clinical trial to evaluate the safety and efficacy of WB001, an investigational therapeutic for postpartum depression (PPD), granted Breakthrough Device designation by the US Food and Drug Administration (FDA) in 2021.

In-Vivo 105

In-Vivo Clinical Trials Clinical Trials Trials 105

The Pharma Data

NOVEMBER 17, 2020

Tony completed his doctoral studies at a Nova Southeastern University , a private university in South Florida. These doctoral studies focused on the comparison of cryopreservation methods of oocytes as well as pre-implantation genetic testing (PGT) of embryos for optimized outcomes. . SARASOTA, Fla. ,

In-Vivo 52

In-Vivo In-Vitro Genetics Doctors 52

The Pharma Data

JANUARY 4, 2021

Kiromic chPD1 has shown in preclinical data to show a cytotoxic response in 9 different in vivo models with 100% long-term PFS with the induction of host memory responses. chPD1 will be used in the Company’s proprietary chimeric antigen receptor therapy (CAR-T) platform using gamma-delta T-cells (GD-T). About Kiromic.

In-Vivo 40

In-Vivo Development Immune Response Big Data 40

XTalks

OCTOBER 1, 2020

Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. However, this has since changed, and now, transitioning between academia and industry has become more commonplace. Key Moments.

Scientist 52

Scientist In-Vitro Research Life Science 52